Description

Pamiteplase CAS NO 151912-42-4 is a recombinant plasminogen activator, a thrombolytic agent engineered for targeted clot dissolution. This compound is critical for pharmaceutical research and development, particularly in the field of cardiovascular therapeutics. It is primarily utilized by biopharmaceutical manufacturers and advanced research institutions focused on developing treatments for acute myocardial infarction and other thrombotic disorders.

Application

• Pharmaceutical Active Ingredient (API): Serves as the core thrombolytic agent in the formulation of injectable drugs for emergency cardiac care.
• Cardiovascular Research: Used in preclinical and clinical studies to investigate mechanisms of fibrinolysis and develop next-generation clot-busting therapies.
• Biopharmaceutical Development: Acts as a key candidate in the development pipeline for biosimilar and novel recombinant protein drugs targeting stroke and pulmonary embolism.
• Reference Standard: Employed as a high-purity standard in analytical laboratories for quality control testing of thrombolytic products.
• Biochemical Reagent: Utilized in enzymatic assays and in-vitro diagnostic (IVD) development to study plasminogen activation pathways.

Basic Information

Product Name	Pamiteplase
CAS No.	151912-42-4
Molecular Formula	C₂₅₈₈H₃₉₈₈N₇₈₀O₈₀₁S₄₀
Molecular Weight	~53 kDa
Synonyms	YM866; Solimase; Pamiteplase (genetical recombination); Recombinant Pamiteplase; Tissue-type plasminogen activator variant; t-PA variant YM866; Plasminogen activator, tissue-type, variant; r-Pamiteplase
EINECS	Contact for details

Quality Control

Our Pamiteplase is manufactured under strict quality management systems. Each batch is subjected to a comprehensive suite of analytical tests including HPLC for purity and potency, electrophoresis for identity and homogeneity, and rigorous testing for endotoxins and bioburden. We provide full traceability and Certificates of Analysis (COA) are available for all shipments, ensuring compliance with cGMP guidelines for pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store frozen at -20°C or below. For long-term storage, maintain at -70°C. The product is hygroscopic (moisture-sensitive). Allow the vial to reach room temperature before opening to minimize condensation. Aliquot reconstituted solutions to avoid repeated freeze-thaw cycles.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (HPLC/Peptide Map)	Conforms to reference standard
Purity (SDS-PAGE & SEC-HPLC)	≥ 98.0 %
Potency (Clot Lysis Assay)	≥ 600,000 IU/mg
Protein Content (UV Absorption)	≥ 95.0 %
Endotoxin (LAL Test)	< 10 EU/mg
Moisture Content (KF)	≤ 3.0 %
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.